RedHill Biopharma (NASDAQ:RDHL) Research Coverage Started at StockNews.com

by · The Markets Daily

StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research report released on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Stock Performance

Shares of NASDAQ RDHL opened at $0.36 on Friday. RedHill Biopharma has a fifty-two week low of $0.26 and a fifty-two week high of $3.28. The firm’s 50-day simple moving average is $0.43 and its 200 day simple moving average is $0.64.

Institutional Investors Weigh In On RedHill Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC bought a new stake in RedHill Biopharma in the third quarter worth about $369,000. Sabby Management LLC bought a new stake in RedHill Biopharma in the third quarter worth about $324,000. Finally, Gagnon Securities LLC raised its position in RedHill Biopharma by 32.1% in the first quarter. Gagnon Securities LLC now owns 118,360 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 28,771 shares in the last quarter. 7.20% of the stock is currently owned by institutional investors.

About RedHill Biopharma

(Get Free Report)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.

Read More